Weight Loss and Reduced Hunger over Four Weeks of Trilogiii Use: A Prospective, Single-Arm Study of a Multi-Target Nutritional Satiety System in 395 Participants, with Separate Extension Cohorts Through Week 12

Abstract

Background. The success of GLP-1 receptor agonists has highlighted sustained satiety as central to weight loss. Trilogiii is a four-product nutritional system designed to support satiety through mechanosensory, hormonal and metabolic (nutrient-repletion) routes, within a framework of complete essential nutrition, gut-microbiome support, and thermogenesis paired with induction of endogenous antioxidant defenses.

Methods. A prospective, single-arm, open-label, nonrandomized study was conducted between July and December 2025. Of 497 people who received the products, 422 submitted results, and 27 returned packets were excluded. Participants were supplied the four products and instructed to use them daily alongside a flexible protocol of water intake and small whole-food meals. Weight and waist/hip circumference were self-reported through paper study packets and/or a private online study group, which all participants were required to join; results in the group were posted as cumulative totals. Volunteers could continue for 4- or 8-week extensions. The co-primary outcomes were 4-week change in self-reported weight and in the frequency of hunger, cravings and food noise.

Results. 395 participants reported 4-week results (257 eligible packet participants and 138 group-only reporters). Mean weight loss was 12.66 lb (95% CI 12.15–13.18; median 11.80); packet participants lost 6.03% of body weight (95% CI 5.82–6.24%), and 180 of 257 (70.0%) lost at least 5%. In separate, self-selected extension cohorts, mean within-period loss was 8.09 lb over weeks 5–8 (n = 91) and 6.37 lb over weeks 9–12 (n = 57). Cumulative totals posted in the study group by reporters in the weight-loss phase averaged 20.85 lb at 8 weeks (n = 101) and 28.25 lb at 12 weeks (n = 65). Among packet participants with paired ratings, 62.3% reported less frequent hunger, 60.8% less food noise (frequency of thoughts about food) and 75.1% less frequent cravings after four weeks, and only 1.7–4.5% reported each as more frequent (sign test, P < 0.001 for each). Reported adverse effects were mainly gastrointestinal and transitional symptoms (such as headache and fatigue) that declined over the four weeks. No participant reported a serious adverse event or needing emergency care; events were self-reported and not independently adjudicated.

Conclusions. In this uncontrolled, self-reported study, Trilogiii with a flexible dietary protocol was associated with substantial short-term weight loss and marked reductions in hunger, cravings and food noise. The design cannot separate product effects from those of the protocol, group support or expectancy, and the formulation’s proposed mechanisms were not measured; a controlled trial is required to confirm these effects and establish the products’ specific contribution.

Study design at a glance

• Prospective, single-arm, open-label, nonrandomized design
• 395 participants reported 4-week results; smaller, separately self-selected cohorts reported for weeks 5–8 and 9–12
• Self-reported weight, waist/hip circumference, and hunger, craving and food-noise frequency, collected through paper study packets and/or a private study group
• Not reviewed by an independent ethics committee and not registered in a public trial registry
• An author-prepared study report published on this site; it has not undergone journal peer review

How to cite

Myhill PR, Murray AJ III. Weight Loss and Reduced Hunger over Four Weeks of Trilogiii Use: A Prospective, Single-Arm Study of a Multi-Target Nutritional Satiety System in 395 Participants, with Separate Extension Cohorts Through Week 12. Triii Therapeutics; November 11, 2026. https://research.triii.life/trilogiii-satiety-study-2026

The full report covers methods, results, discussion, limitations, declarations (funding, conflicts of interest, ethics and data availability) and appendices. Questions and data-verification requests go to the corresponding author at research@triii.life.